CA2659562A1 — Stable lyophilized preparation
Assigned to Eisai R&D Management Co Ltd · Expires 2008-02-21 · 18y expired
What this patent protects
Disclosed is a lyophilized preparation comprising (8E,12E,14E)-7-((4-cycloheptylpiperazin-1-yl)carbonyl)oxy- 3,6,16,21-tetrahydroxy-6,10,12,16,20-pentamethyl-18,19- epoxytricosa-8,12,14-trien-11-olide, which has excellent long-term stability and excellent solubility upon dissolve…
USPTO Abstract
Disclosed is a lyophilized preparation comprising (8E,12E,14E)-7-((4-cycloheptylpiperazin-1-yl)carbonyl)oxy- 3,6,16,21-tetrahydroxy-6,10,12,16,20-pentamethyl-18,19- epoxytricosa-8,12,14-trien-11-olide, which has excellent long-term stability and excellent solubility upon dissolved in water. Specifically disclosed is a lyophilized preparation comprising 1) (8E,12E,14E)-7-((4-cycloheptylpiperazin-1- yl)carbonyl)oxy-3,6,16,21-tetrahydroxy-6,10,12,16,20- pentamethyl-18,19-epoxytricosa-8,12,14-trien-11-olide or a pharmacologically acceptable salt thereof, 2) a pH-adjusting agent for adjusting the pH value of the preparation to 5 to 8, and 3) at least one excipient selected from a sugar and a sugar alcohol.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.